Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)

被引：7

作者：

Janzic, Urska ^{[1
]}

Turnsek, Nina ^{[2
]}

Dediu, Mircea ^{[3
]}

Donev, Ivan Shterev ^{[4
]}

Lupu, Roxana ^{[5
]}

Teodorescu, Gabriela ^{[5
]}

Ciuleanu, Tudor E. ^{[6
]}

Pluzanski, Adam ^{[7
]}

机构：

[1] Univ Clin Resp & Allerg Dis, Med Oncol Dept, Golnik 4204, Slovenia

[2] Inst Oncol Ljubljana, Med Oncol Dept, Ljubljana 1000, Slovenia

[3] Sanador Oncol Ctr, Bucharest 010991, Romania

[4] MHAT Nadezhda, Dept Med Oncol, Sofia 1330, Bulgaria

[5] AstraZeneca Romania, Med Dept, Bucharest 013713, Romania

[6] Oncol Inst Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca 400015, Romania

[7] Maria Sklodowska Curie Natl Res Inst Oncol, Lung Canc & Chest Tumours Dept, PL-02781 Warsaw, Poland

来源：

CURRENT ONCOLOGY | 2022年 / 29卷 / 08期

关键词：

real-world retrospective study; advanced non-small cell lung cancer; EGFR T790M mutation; TYROSINE KINASE INHIBITOR; OSIMERTINIB; RESISTANCE;

D O I：

10.3390/curroncol29080460

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored EGFR/T790M testing and treatment patterns in EGFRm NSCLC patients receiving first- or second-generation (1G/2G) EGFR TKIs as front-line (1L) in eight countries. Pooled data from Central Eastern Europe (CEE) countries from this study (Bulgaria, Poland, Romania, Slovenia) are presented here. This physician-led chart review study was conducted in patients with confirmed-EGFRm NSCLC initiating 1L 1G/2G EGFR TKIs between 2015-2018. The CEE cohort included 389 patients receiving 1L erlotinib (37%), afatinib (34%), and gefitinib (29%). Overall, 320 (82%) patients discontinued 1L, and 298 (77%) progression events were registered. Median progression free survival on 1L TKIs was 14.0 (95% CI: 12.6-15.6) months. Median overall survival from 1L start was 26.6 (95% CI: 24.1-29.0) months. Attrition rate between 1L and next line was 30%. Among patients with 1L progression, 200 (67%) were tested for T790M and 58% were positive. This first CEE analysis of treatments and outcomes in EGFRm NSCLC patients highlights the importance of using the most efficacious therapies currently available in 1L to reduce attrition and improve patient outcomes.

引用

页码：5833 / 5845

页数：13

共 38 条

[1] Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT) [J].

Addeo, Alfredo ;

Hochmair, Maximilian ;

Janzic, Urska ;

Dudnik, Elizabeth ;

Charpidou, Andriani ;

Pluzannski, Adam ;

Ciuleanu, Tudor ;

Donev, Ivan Shterev ;

Elbaz, Judith ;

Aaroe, Jorgen ;

Ott, Rene ;

Peled, Nir .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

[2] Cancer mortality in Europe in 2015 and an overview of trends since 1990 [J].

Bertuccio, P. ;

Alicandro, G. ;

Malvezzi, M. ;

Carioli, G. ;

Boffetta, P. ;

Levi, F. ;

La Vecchia, C. ;

Negri, E. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1356-1369

[3] EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors [J].

Chiang, Anne C. ;

Fernandes, Ancilla W. ;

Pavilack, Melissa ;

Wu, Jennifer W. ;

Laliberte, Francois ;

Duh, Mei Sheng ;

Chehab, Nabil ;

Subramanian, Janakiraman .

BMC CANCER, 2020, 20 (01)

[4] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

[5] Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study [J].

Cuppens, Kristof ;

Lodewyckx, Liesbet ;

Demedts, Ingel ;

Decoster, Lore ;

Colinet, Benoit ;

Deschepper, Koen ;

Janssens, Annelies ;

Galdermans, Daniella ;

Pieters, Thierry .

DRUGS-REAL WORLD OUTCOMES, 2021, 8 (02) :141-152

[6]

EMA, 2016, EMA

[7]

EMA, 2018, EMA EUR EU DOC SMOP

[8] Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? [J].

Facchinetti, F. ;

Leonetti, A. ;

Tiseo, M. .

ANNALS OF ONCOLOGY, 2020, 31 (11) :1581-1582

[9] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) [J].

Gelatti, Ana C. Z. ;

Drilon, Alexander ;

Santini, Fernando C. .

LUNG CANCER, 2019, 137 :113-122

[10]

Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI [10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48]

← 1 2 3 4 →